Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more
Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Maternal undernutrition and cardiometabolic disease: a latin american perspective

  • Patricio Lopez-Jaramillo1, 2Email author,
  • Diego Gomez-Arbelaez2, 4,
  • Aristides Sotomayor-Rubio3,
  • Daniel Mantilla-Garcia3 and
  • Jose Lopez-Lopez3
BMC Medicine201513:41

https://doi.org/10.1186/s12916-015-0293-8

Received: 1 October 2014

Accepted: 12 February 2015

Published: 2 March 2015

Abstract

The current epidemic of obesity and cardiometabolic diseases in developing countries is described as being driven by socioeconomic inequalities. These populations have a greater vulnerability to cardiometabolic diseases due to the discrepancy between the maternal undernutrition and its consequence, low-birth weight progeny, and the subsequent modern lifestyles which are associated with socioeconomic and environmental changes that modify dietary habits, discourage physical activity and encourage sedentary behaviors. Maternal undernutrition can generate epigenetic modifications, with potential long-term consequences. Throughout life, people are faced with the challenge of adapting to changes in their environment, such as excessive intake of high energy density foods and sedentary behavior. However, a mismatch between conditions experienced during fetal programming and current environmental conditions will make adaptation difficult for them, and will increase their susceptibility to obesity and cardiovascular diseases. It is important to conduct research in the Latin American context, in order to define the best strategies to prevent the epidemic of cardiometabolic diseases in the region.

Keywords

ObesityCardiovascular diseasesMaternal undernutritionLow-birth weightSocio-economic inequalitiesLatin AmericaDeveloping countries

Introduction

Overweight and obesity are defined as a body mass index (BMI) of 25–29.9 and greater than or equal to 30 kg/m2, respectively. Worryingly, prevalence is increasing at an alarming rate throughout the world and it has been projected that in 2030, there will be 2.16 billion overweight and 1.12 billion obese people in the world [1]. Developing countries have seen a proportionally larger increase in the number of overweight and obese individuals. For instance, some years ago it was reported that a third of the population in Latin America were overweight or obese [2,3], whereas current data suggests that it has increased to around half of the adults [4].

This trend is thought to be driven by the rapid and unequal socio-economic development that Latin America is experiencing. Significant nutritional changes, including increases in high energy density foods consumption, with a parallel decreases in physical activity levels, due to the mechanization of both daily work and leisure-time activities [5-8], are being observed. Moreover, the migration from rural to urban areas could be also contributing to these lifestyle changes [9].

Despite the increased prevalence of obesity and overweight, maternal undernutrition and its consequence, low-birth weight progeny, remains an important public health concern in many developing regions, such as Latin America [10]. This condition may be also a consequence of the unequal socio-economic development observed in the region, since both maternal undernutrition and placental dysfunction induced by preeclampsia or infections, can lead to intrauterine growth restriction (IUGR) [11]. Indeed, socio-economic inequality is a determinant of poor access of pregnant women belonging to a low socio-economical stratum to an adequate diet and to an appropriate prenatal care [10,12], in turn risk factors for the mentioned placental disorders, and hence, for IUGR.

Interestingly, it has been demonstrated that a poor nutrition during the fetal development and early in the extra uterine life is associated with increased risk of cardiometabolic disease in adulthood [13,14]. Therefore, the main goal of this review is to explain, from our point of view, how the socio-economic inequality mediated by a mismatch between maternal undernutrition and exposure to westernized lifestyles in later life is contributing to the current increasing prevalence in obesity and cardiometabolic diseases in the Latin American population. Moreover, we will review the association between these trends and epigenetic adaptations, insulin resistance and low-degree inflammation.

The Cardiometabolic disease situation in Latin America

There have been large shifts in the morbi-mortality trends in Latin America in recent decades, moving from a dominance of transmissible to a dominance of non-transmissible chronic diseases, including cardiovascular and metabolic diseases [2,5,9,15]. For example, while national, regional and global trends in fasting plasma glucose and diabetes prevalence since 1980 [16], show that glycemia levels and type 2 diabetes mellitus (DM2) are an increasing hazard worldwide (Table 1); higher prevalences are reported in some regions, including Oceania and Latin America. In fact, the estimated increase in the number of people with DM2 in Latin America will be over 150% in just three decades, from 15 million in 1995 to 39 million in 2025 [17]. Results of small studies confirm these exceptionally high prevalences of DM2, such as values as high as 43.3% in Puerto Rico [18]. The lowest prevalence has been reported in Peru (5% in Lima) [19].
Table 1

Global trends in fasting plasma glucose and diabetes prevalence (1980 vs. 2008)

Variables

1980

2008

Global FPG (mmol/L)*

  

Men

5.29**

5.50 (5.37–5.63)

Women

5.15**

5.42 (5.29–5.54)

DM2 prevalence (%)*

  

Men

8.3 (6.5–10.4)

9.8 (8.6–11.2)

Women

7.5 (5.8–9.6)

9.2 (8.0–10.5)

People with DM2 (million)*

  

Men

77 (60–97)

173 (151–197)

Women

76 (58–97)

173 (151–197)

*Age-standardized values. **Estimated values from the published data [16]. Data is presented as mean (95% uncertainty interval). FPG: fasting plasma glucose. DM2: diabetes mellitus type 2.

In relation to obesity, a systematic analysis reported by the Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group demonstrated that between 1980 and 2008, the mean BMI increased worldwide by 0.4 kg/m2 per decade for men and 0.5 kg/m2 per decade for women. In Latin America the largest rise in BMI occurred in females, in which rises of 1.3 kg/m2 per decade were observed [20]. In global terms it is clear that the poorest countries in Latin America, such as Haiti, Honduras and Bolivia, have the lowest rates of obesity. However, similar rates of increase are observed in these countries as in the region as a whole [1,3], being higher in women, and disproportionately affecting groups from lower socio-economic strata who are living in urban areas [3].

Moreover, the metabolic syndrome (MetS) has been always considered as a major public health concern. It was first described predominantly in developed countries such as the United States, where a prevalence of 24% in the adult population was reported [21]. Nonetheless, various further studies in Latin American countries [19,22-28], have demonstrated that currently these countries have a similar or even higher prevalence of MetS in adults than developed countries (Table 2).
Table 2

Prevalence of metabolic syndrome in Latin American countries

Country

Year

Participants (n)

Age (years)

Diagnostic criteria

MS prevalence (%)

Chile

2003

1833

≥17

ATP-III

32.0

IDF

37.0

Mexico

2006

6021

20 to 69

ATP-III

36.8

IDF

49.8

Venezuela

2001

3108

≥20

ATP-III

31.2

Ecuador

2004

352

≥65

IDF

40.0

Peru

2006

1878

20 to 80

AHA/NHLBI

18.8

Brazil

2001

1655

25 to 64

ATP-III

32.9

Colombia

2007

1001

≥18

ATP-III

45.6

IDF

50.4

Extracted values from published data [19,22-28]. MS: metabolic syndrome.

Less data is available about the prevalence of MetS and its components in children and adolescents in Latin America. A small study of children and adolescents of Bolivia reported a high frequency of MetS (36% of the sample) [29], and in another recent study, in Chilean adolescents 37.5% presented with MetS [30]. Therefore, while malnourishment remains a large problem in a substantial proportion of poor Latin American children, obesity is emerging in alarming rates, principally in the most developed sectors in these countries [8]. For example, we recently reported a lower prevalence of undernutrition (4.4%) in school age Colombian children than of overweight (12.9%) and obesity (9.8%) [31].

The non-communicable chronic disease situation in Latin America is one that is of concern not only in terms of prevalence, but also due to its low rates of awareness, treatment and control. The Prospective Urban and Rural Epidemiology (PURE) study, in which 4 Latin American countries (Argentina, Brazil, Colombia and Chile) are currently participating, recently reported worrisome global and regional rates of awareness, treatment and control of hypertension [32], as well as a very low use of the proven effective secondary preventive drugs in those patients with a previous history of coronary heart disease or stroke [33]. Moreover, among these individuals with self-reported coronary heart disease or stroke, the prevalence of a healthy lifestyle was also very low (Table 3) [34]. The Latin American situation is of concern when compared to high-income countries. The above situations are other examples of the poor access to adequate health care in our population, so as it is prenatal care for mothers.
Table 3

Global and Latin American rates of awareness, treatment and control of cardiovascular diseases – PURE study

Variables

Global prevalence (%)

Latin American prevalence (%)

Hypertension

  

 Awareness

46.5

57.1

 Treatment

40.6

52.8

 Control

13.2

18.8

Secondary preventive drugs

  

 Antiplatelet drugs

25.3

29.0

 β-blockers

17.4

28.8

 ACE / ARB

19.5

37.9

 Statins

14.6

15.0

Healthy lifestyle

  

 Smoking cessation

53.4

67.2

 Physical activity

35.1

41.5*

 Healthy diets

39.0

43.2*

Extracted values from published data [32-34]. *Data for the global lower-middle-income countries, where the Latin Americans are included. ACE: angiotensin-converting-enzyme inhibitors. ARB: angiotensin-receptor blockers.

In this context, the social and financial costs of obesity and cardiometabolic diseases are also increasing at excessively high rates. Certainly, premature mortality and temporary and permanent disability generated as complications of non-communicable chronic diseases represent an enormous burden for patients and their families, as well as for the health system and society in general [35]. For example, obesity has been shown to account for up to 16% of the global burden of disease, expressed as a percentage of disability-adjusted life-years. Moreover, there has been described that around of 10% of total health care costs in the developed world are attributable to obesity [36]. This is especially worrisome in emerging economies, such as Latin Americans.

Several strategies have been implemented to reduce the burden of cardiovascular diseases (CVD) in Latin America. For instance, recently the Latin American consensus on hypertension in patients with DM2 and MetS was published [37] to serve as a guide for physicians taking care of patients with these diseases and comorbidities. In addition, the Latin American Society of Hypertension (LASH) defined ‘the initiative 20/20’ as an institutional goal, which aims to improve the awareness, treatment and control of hypertension in 20% by the year 2020 [38]. Unfortunately, all these important actions are only mitigating the problem, but do not address the causes of non-communicable chronic diseases. We therefore believe that several public health policies should be adopted which are aimed at reducing social inequality in our region, since it is underlies the link between early life conditions, including intrauterine, and the regional epidemic of cardiometabolic diseases in later life, as we are going to review below.

Maternal undernutrition, epigenetics and cardiometabolic diseases

Inter-population differences in the prevalence of cardiovascular and metabolic diseases and its associated risk factors may reflect differences in the quality of life status between them, which could be influenced by several environmental factors, such as physical activity and dietary patterns. However, genetic background might also play a key role, since the genome is programmed to express appropriate sets of genes, in particular tissues, at specific time points during the individual’s life. Even more important however, may be the genetic-environment interaction in the pathogenesis of cardiometabolic diseases, which can induce epigenetic modifications [10,13,14].

By definition, epigenetics refers to modifications in gene expressions that are controlled by changes in DNA methylation and/or chromatin structure [39], and might play an important role in the pathogenesis of various entities, including cancer and cardiometabolic diseases. Epigenetic events are heritable, although occasionally reversible, depending on endogenous, but specially exogenous (environmental) signals, creating a memory of cell identity [40], and maintaining genomic functions after differentiation, propagation of essential features of chromosomal architecture, and dosage compensation [41]. Therefore, epigenetic modifications could lead to irreversible processes of differentiation and organogenesis or to labile and potentially reversible changes in homeostatic processes [14]. Moreover, environmental signals such as food depletion and stress have been present throughout evolution, and organisms have had to sense and adapt to them, to ensure their survival. These epigenetic modifications occur not only in humans, but have also been implicated in the control of various parameters of gene expression, genetic recombination, DNA repair, and DNA mutagenesis in bacteria, plants, and animals [42].

Epigenetic mechanisms include DNA methylations, histone modifications, and microRNAs [43], and can help to explain how individuals with identical or similar DNA, when exposed to different environmental signals, express diverse phenotypes and differ in their susceptibility to certain pathologies. Thus, chromatin structure can be linked to environmental factors such as diet, nutrients, drugs or the socio-economic environment in several ways [40,44]. From this perspective, we propose that the very rapid change from undernutrition to overnutrition in Latin American and the Caribbean countries [3-5], a consequence of the socio-economic transition process, may be producing an epigenetic maladaptation in these populations.

There is an interesting discrepancy between developed and developing countries, and the causal direction of the relationship between socio-economic conditions and obesity and CVD is complex. In developing countries, at the start of the epidemiologic and nutrition transition, a higher socio-economic level was associated with a more unhealthy diet and higher levels of obesity, while over time a gradual shift and reversal of this relationship has been observed. Currently, higher socio-economic status is associated with knowledge of good nutrition and lifestyle choices and an inverse relation between socio-economic levels and obesity is being observed, as found in developed countries. Meanwhile, later in the transition process, poorer people in developing countries have adopted increasingly unhealthy lifestyles and changes in their nutritional habits [5,7,8], trends currently occurring in the Latin American population. Thus, in these populations, westernized habits of high energy intake and low energy expenditure during adulthood contrast substantially with the epigenetic fetal programming based on maternal conditions of undernutrition, thereby mediating an increased susceptibility to high incidence of cardiovascular and metabolic diseases (Figure 1).
Figure 1

Epigenetic modifications and environmental influences on the pathogenesis of cardiometabolic diseases.

During early human and animal development, exogenous or environmental signals and changes could induce epigenetic modifications, which have potential long-term consequences [40,45]. In some populations, poor maternal nutrition has been associated with increased risk of DM2 over several generations [14,46]. Moreover, placental insufficiency, inadequate maternal nutrition, metabolic disturbances or neonatal medication can induce incorrect epigenetic programming during early development, which could partially explain lifelong imbalance between energy intake and energy expenditure in individuals with MetS, obesity, DM2 and CVD [14,46-51].

Indeed, human epidemiological studies and appropriately designed dietary interventions in animal models have provided considerable evidence to suggest that maternal nutritional imbalance and metabolic disturbances, during critical time windows of development, may have a persistent effect on the health of offspring and may even be transmitted to the next generation [14,47,52-57]. As a consequence, the hypotheses of “fetal programming” and its new denomination: “developmental origins of health and disease” were proposed, describing the early nutrition during gestation and lactation as a common risk factor for chronic diseases, such as obesity, CVD, diabetes, hypertension, asthma, cancer and even schizophrenia [58-66].

Furthermore, cohort studies after famine also suggest that several adulthood diseases are related to the duration and timing of nutritional deficit during the gestational period. As epigenetic plasticity changes continuously from conception to death, effects will vary according to whether the exposure occurs during preconception, pregnancy, lactation, neonatal life, early life, pre-/post-menopause, or puberty [53]. Furthermore, several other processes, such as chromosomal instability, telomere shortening, metabolic cycles, mitochondrial deteriorations, and oscillatory, circadian or seasonal rhythms of systemic hormone levels (hypothalamic–pituitary–adrenal axis), could also affect epigenetic plasticity [50,52,58,59,67-70]. In principle, the earlier the epigenetic changes occur, the greater their physiologic/metabolic impact such that epigenetic modifications that occur during embryogenesis and early fetal development would be transmitted over consecutive mitotic divisions, affecting many more cells than those occurring during postnatal development [55]. Data from the Dutch Winter Hunger cohort revealed that those descendants of mothers who were severely undernourished during the early stage of pregnancy were more likely to develop CVD than those born to mothers whose pregnancies were more advanced at the time of nutritional deficit [71-73].

Various conditions and nutritional restrictions during pregnancy have been linked with a number of different metabolic outcomes on their offspring in humans and animals. Low maternal protein consumption or poor vitamin B and methionine status are associated with behavioral and cardiovascular abnormalities, and sex-specific changes in hepatic gene expression in rat fetuses and changes in imprinted gene expression in the rat embryo-fetal axis [40,74-76]. Katari et al. [77] highlighted the association between in-vitro conception and changes in DNA methylation, in turn affecting the long-term pattern of expression of genes involved in chronic metabolic disorders such as obesity and DM2. Pinney and Simmons [78] studied epigenetic events at the promoter of the gene encoding Pdx-1, a critical transcription factor (TF) for beta-cell function and development, the expression of which is reduced in intra uterine growth restriction (IUGR), a situation that has been associated with the development of diabetes in adulthood [15,40,78]. As mentioned above, IUGR can be a consequence of maternal undernutrition and can predispose to the development of DM2 in the new born when exposed to different, energy-rich diet in later life [10,13]. Raychaudhuri et al. [79] focused on the sequence of epigenetic mechanisms responsible for the weak expression of Glut-4 in the skeletal muscle of individuals with IUGR. They found that perinatal nutrient restriction resulting in IUGR leads to histone modifications in skeletal muscle that directly decrease Glut-4 gene expression. This effectively creates a metabolic knockdown of an important regulator of peripheral glucose transport and insulin resistance, thereby contributing to the adult DM2 phenotype [79].

In addition, it has been demonstrated that IUGR may be related to such vascular abnormalities as stiffness of the abdominal aorta [80], reduced arterial compliance [81], narrower retinal arteriolar caliber [82], and endothelial dysfunction [83], factors which also contribute to the development of CVD later in life. Maternal protein restriction during pregnancy may also result in a declined skeletal muscle mass of the progeny [84]. In a recent study it was shown in IUGR pigs that their total number of muscle fibers was lower when compared with normal body weight animals [85]. Furthermore, there was altered the expression of 37 proteins involved in the proliferation and differentiation of muscle fibers, energy supply, protein metabolism, nutrient transport, intracellular environment, and tissue integrity. We recently demonstrated in a population of Colombian children from low socio economical strata, an association between low muscle strength and increased levels of adipocytes, C-reactive protein (CRP), HOMA index and metabolic risk factors [31]. Moreover, in a sub-analysis of the ORIGIN study [86] we demonstrated that low handgrip strength is an important factor associated to an increased risk of cardiovascular mortality in prediabetic and diabetic patients.

Furthermore, even pre-implantation development in mammals has recently been shown to be sensitive to environmental conditions [87]. Results of both in-vivo and in-vitro experiments, have demonstrated that environmental factors can modify blastocyst potential and lead to long-term changes in fetal and postnatal health and physiology. For example, elevated concentrations of plasma homocysteine have been found in pre-implantation embryos, which have low mtDNA copy number and subsequently develop DM2 [88]. Similarly, the environment inhabited by breeding females before conception and early in pregnancy has striking effects on the oocytes developing in the ovarian follicle and embryos in the early stages of development in the reproductive tract. Environmental conditions at these stages may also alter behavior, cardiovascular function and reproductive function throughout postnatal life [40,89-92].

Consequently, fetal and neonatal periods are critical for the development and growth of the systems involved in cardiometabolic pathways. In rats, detrimental effects on growth during fetal and early postnatal life can negatively affect both the number [93] and secretor function of pancreatic beta-cells [94]. Some years ago, Hales and colleagues demonstrated that men with a low-birth weight were six times more likely to have DM2 at 64 years of age than men with a high-birth weight [95]. Moreover, it has been demonstrated that children who had a low-birth weight but had increased rates of growth at 7 years old had a further increased risk of developing DM2 later in life [96]. Hence, it is interesting to propose that the increased rates of cardiovascular and metabolic diseases, currently observed in Latin America could be the result of the discrepancy between the restricted nutritional environment during fetal development and early life, and the environment of nutritional abundance during adulthood. This discrepancy causes a mismatch between the fetal programming of the organism’s metabolic pathways and their adult circumstances, characterized by the imposition of new obesogenic lifestyles [5,10,13,15].

Moreover, recent studies have found significant differences in DNA methylation profiles in aged monozygotic twins with a history of non-shared environments, suggesting that environmentally mediated epigenetic changes also occur throughout life [97,98]. For example, important CVD risk factors such as hypercholesterolemia, obesity, hyperhomocysteinemia, and hyperglycemia could stimulate the inflammatory process and its long-term effects via epigenetic reprogramming, promoting differentiation of monocytes/macrophages into more pro-atherogenic phenotypes [99-102].

Abdominal obesity, insulin resistance and low degree inflammation

Overweight and obesity have been well described as important risk factors for CVD [12,103,104] and DM2 [3,5,103], and to be associated with an increased prevalence of other cardiovascular risk factors [103]. Recently, in Colombian adults with severe coronary disease, we reported that abdominal obesity is associated with leptin/adiponectin imbalance, decreased endothelium-dependent relaxation and an enhanced response to angiotensin-II. These changes occurred independently of other cardiovascular risk factors and therefore suggest that these vascular alterations, promoted by abdominal obesity, could be the initial event that leads to insulin resistance, low degree inflammation, atherosclerosis and CVD [104].

Moreover, the INTERHEART [105] and the INTERSTROKE [106] studies, which included Latin American countries (Argentina, Brazil, Chile, Colombia, Ecuador, Peru), demonstrated that abdominal obesity, evaluated by waist-to-hip ratio, was a more sensitive risk factor than BMI in subjects that presented a first event of myocardial infarction and stroke. Furthermore, abdominal obesity is considered as the key factor in the onset of MetS, a cluster of hypertension, dysglycemia, low HDL cholesterol, increased triglycerides, and abdominal obesity. MetS is also related to an increased risk of DM2 and CVD [107], an important consideration given that abdominal obesity is highly prevalent in Latin America.

A recent report of the International Day for Evaluation of Abdominal Obesity (IDEA) study [108], showed that the mean waist circumference in a Latin American primary care population was 96.4 cm and 89.7 cm for men and women, respectively. This study also confirmed the association between increased abdominal obesity and the presence of DM2 and CVD in our population. However, the cutoff point to diagnose abdominal obesity in the Latin American population remains controversial. A study conducted in Colombian subjects with no previous CVD history, reported that the criteria for waist circumference proposed by the International Diabetes Federation (90 cm: men, 80 cm: women) is more useful for identifying subjects with MetS than that proposed by the Adult Treatment Panel III (102 cm: men, 88 cm: women) [22]. In addition, several studies [109,110] carried out in developing countries have reported lower waist circumference cutoff points for cardiovascular risk than those reported in developed countries. In healthy young Colombian men, a waist circumference of 88 cm identified subjects with cardiovascular risk with a sensitivity of 83.7% and a specificity of 84.8% [111]. In Ecuador [112], it was demonstrated that a waist circumference of 90 cm in men is the best cutoff point associated with the presence of at least two of the other MetS criteria according to the Adult Treatment Panel III.

Recently, it has become evident that the visceral adiposity content is crucial in determining risk of developing DM2 and CVD [113]. Waist circumference was reported to be an easy to implement measure for evaluating the content of visceral fat, which is the main source of pro-inflammatory cytokines [113-116]. Moreover, some studies have observed that the concentration of pro-inflammatory cytokines is higher in the Latin American population than that reported in the population of developed countries, suggesting a higher sensitivity of this population to develop systemic low-degree inflammation in response to abdominal obesity [117,118]. These cytokines are elevated in the serum of obese subjects [119] and it has been proposed that the systemic inflammation produced by the adipose tissue participates in all stages of the development of cardiometabolic diseases, such as endothelial dysfunction [120], atheroma formation, rupture of plaque, and acute thrombotic complications [121,122]. C-reactive protein (CRP), produced by the liver in response to the stimulus of TNF-alpha and interleukin-6, is increased in subjects with multiple acute coronary events and is a strong independent predictor of new acute coronary events [123]. We have demonstrated in the Andean region that CRP is an independent risk factor for essential hypertension [124] and preeclampsia [125,126]. Moreover, the concentration of CRP is increased in dyslipidemic subjects with MetS [127] and in overweight children [128].

All these studies confirm that Latin Americans have an increased risk of developing cardiometabolic diseases at lower levels of abdominal obesity. We propose that this observation could be mediated by epigenetic modifications acquired during fetal development, which could affect visceral adipose tissue and predispose to an inflammatory imbalance. Recently, we found evidence of regional differences in adiponectin levels in subjects with MetS, especially between developed vs. developing countries [129]. However, we were not able to ascertain whether the lower adiponectin values observed in subjects with MetS from developing countries were related to genetic and or epigenetic factors. Therefore, additional studies are required to further test this hypothesis.

Inflammation has been described as an adaptation to the disruption of homeostasis at a cellular and tissue level and affects many important processes, such as host defense, tissue remodeling and repair, and the regulation of metabolism. All of processes related to the inflammatory response require coordinated control in some conditions, and independently in others [130,131]. This is accomplished with the participation of several mechanisms that operate at different levels, including alterations in the composition of immune cells in tissues, changes in cell responsiveness to inflammatory stimuli, regulation of signaling pathways and epigenetic control of gene expression [66].

For example, signal-specific mechanisms operating at the molecular level can activate the key transcription factor (TF) nuclear factor-kB (NFkBTF), which is probably the most important TF and mediator of inflammation, since it controls the expression of more than 400 genes [132-134]. In addition, NFkBTF is involved in increasing inflammatory disease and malignancy by inducing transcription of soluble mediators that amplify inflammation, angiogenesis and neoplastic cell proliferation, and promoting progression to more aggressive disease states [135]. Moreover, infectious agents and over nutrition, specifically via metabolic and endoplasmic reticulum (ER) stress, are some of the numerous stimuli that can activate to NFkBTF family. Indeed, a considerable constitutive activity of NFkBTF and its associated processes has been observed in many cancer cells, inflammatory disorders, obesity and insulin resistance [132,133,136-143].

Obesity is characterized by a chronic exposure to high energy intake and positive energy balance, and ER is the organelle responsible for responding to these challenges. ER acts as a key nutrition sensor of cellular metabolic parameters, such as hyperglycemia, fatty acid overload, hypoglycemia, and oxidative stress, and participates in almost all anabolic and catabolic processes. Therefore, an eventual failure of the ER’s adaptive capacity would affect many different inflammatory and stress signaling pathways at the crossroad of inflammation, cancer and metabolic disease [138,139,144].

Besides the molecular and cellular levels, there are some gene-specific mechanisms operating at the level of individual genes and gene subsets. Several TF and extragenic noncoding RNAs participate in the induction of inflammatory transcriptional responses by acting on inflammatory enhancers [145-148]. Hence, a well-ordered expression of cytokine genes is a crucial component of an immune response and is decisive for homeostasis. Various factors, including the type of cytokine, as well as the cell type, dose range and the kinetics of its expression are extremely important to generate an appropriate response to metabolic stress or an infectious condition [149-151]. Recently, several efforts have been made to modulate epigenetic factors, such as via hyper/hypomethylation of key inflammatory genes by external and dietary factors, aiming to cure or protect against inflammatory disease [53,152-156].

Different cell types constitutively express primary-response TF in their cytoplasm and these are activated by signal-dependent post-translational modifications, which involve their nuclear translocation, such as NFkB, IRF, and CREB. These transcription factors are mainly responsible for the primary phase of gene induction and integrate signals from diverse signaling pathways that can amplify or terminate signal-dependent TF activation. Other classes of TF, such as C/EBPd, require de novo synthesis following inflammatory stimulation. Most are constitutively nuclear and regulate secondary waves of gene expression. Other class of constitutively nuclear TF is expressed in a cell type-specific and differentiation-dependent manner, such as Runx, PU.1, IRF8, AP1, and C/EBP [146,157]. They establish cell type-specific patterns of gene expression and are involved in chromatin remodeling during cell differentiation and organization of high-order chromatin structure and chromosomal domains. The TF of these categories do not act independently, but function coordinately to control the inflammatory transcriptional response. Upon combining datasets of expression profiling of inflammatory genes and in silico motif scanning of promoters of these genes they can define gene clusters that are coordinately regulated and the TF that are likely to control their expression [130,132,134,141,149,157-160]. As TF bind very poorly, or not at all, to nucleosomal DNA, their activation is therefore coordinated to the recruitment of ATP-dependent chromatin-remodeling factors, histone-enzyme complexes, methylases, demethylases, acetylases, and deacetylases, amongst other substances. Parallel post-translational modifications such as phosphorylation, acetylation, methylation, ribosylation, sumoylation, and ubiquitination of histone and non-histone TF and cofactor complexes, permit formation of dynamic enhanceosome complexes which establish a distinct chromatin structure. Ultimately, all of these epigenetic reactions and modifications are the decisive step in which both environmental and differentiative inputs determine the correct or incorrect expression of each inflammatory gene [66,132,158,160-162].

Conclusion

Socioeconomic inequalities are emerging as an important determinant of the current worldwide epidemic of obesity and CVD. While the relationship between socioeconomic conditions and obesity and CVD is inconsistent in developed countries, in developing countries there appears to be a strong association between the two. As a possible explanation, it is suggested that in developing countries maternal disadvantage leads to a low-birth weight as a consequence of poor health behaviors, exposure to harmful environmental factors, poorer access to medical care, and less worse underlying maternal health. Later in life, due to the socioeconomic transition, these children have been exposed to a greater access to energy-dense diets, and an increased risk of developing obesity and CVD. We therefore argue that a key solution to address this public health concern is the implementation of public policies which aim to reduce socioeconomic inequalities. Despite having achieved some important goals, it is noteworthy that we are fighting a huge enemy - the increasing epidemic of CVD driven by our social inequalities. Therefore, the great challenge is to continue to develop and implement research in our population which aims to find regional-specific solutions to resolve a worldwide problem.

Abbreviations

BMI: 

Body mass index

CRP: 

C-Reactive protein

CVD: 

Cardiovascular diseases

DM2: 

Diabetes mellitus type 2

ER: 

Endoplasmic reticulum

IUGR: 

Intrauterine growth restriction

MetS: 

Metabolic syndrome

TF: 

Transcription factor

Declarations

Authors’ Affiliations

(1)
Dirección de Investigaciones, Fundación Oftalmológica de Santander – FOSCAL
(2)
Instituto de Investigaciones MASIRA, Universidad de Santander – UDES
(3)
Escuela de Medicina, Universidad Autónoma de Bucaramanga – UNAB
(4)
Departamento de Endocrinología, Escuela de Medicina, Universidad de Santiago de Compostela - España

References

  1. Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond). 2008;32:1431–7.Google Scholar
  2. Cuevas A, Alvarez V, Carrasco F. Epidemic of metabolic syndrome in Latin America. Curr Opin Endocrinol Diabetes Obes. 2011;18:134–8.PubMedGoogle Scholar
  3. Cuevas A, Alvarez V, Olivos C. The emerging obesity problem in Latin America. Expert Rev Cardiovasc Ther. 2009;7:281–8.PubMedGoogle Scholar
  4. Rueda-Clausen CF, Silva FA, López-Jaramillo P. Epidemic of overweight and obesity in Latin America and the Caribbean. Int J Cardiol. 2008;125:111–2.PubMedGoogle Scholar
  5. Lopez-Jaramillo P, Lahera V, Lopez-Lopez J. Epidemic of cardiometabolic diseases: a Latin American point of view. Ther Adv Cardiovasc Dis. 2011;5:119–31.PubMedGoogle Scholar
  6. Uauy R, Albala C, Kain J. Obesity trends in Latin America: transiting from under- to overweight. J Nutr. 2001;131:893S–9S.PubMedGoogle Scholar
  7. Lear SA, Teo K, Gasevic D, Zhang X, Poirier PP, Rangarajan S, et al. The association between ownership of common household devices and obesity and diabetes in high, middle and low income countries. CMAJ. 2014;186:258–66.PubMedPubMed CentralGoogle Scholar
  8. Gómez-Arbeláez D, Camacho PA, Cohen DD, Rincón-Romero K, Alvarado-Jurado L, Pinzón S, et al. Higher household income and the availability of electronic devices and transport at home are associated with higher waist circumference in Colombian children: the ACFIES study. Int J Environ Res Public Health. 2014;11:1834–43.PubMedPubMed CentralGoogle Scholar
  9. Barría RM, Amigo H. Nutrition transition: a review of Latin American profile. Arch Latinoam Nutr. 2006;56:3–11.PubMedGoogle Scholar
  10. López-Jaramillo P. Cardiometabolic disease in Latin America: the role of fetal programming in response to maternal malnutrition. Rev Esp Cardiol (Engl Ed). 2009;62:670–6.Google Scholar
  11. Negrato CA, Gomes MB. Low birth weight: causes and consequences. Diabetol Metab Syndr. 2013;5:49.PubMedPubMed CentralGoogle Scholar
  12. Lopez-Jaramillo P. Defining the research priorities to fight the burden of cardiovascular diseases in Latin America. J Hypertens. 2008;26:1886–9.PubMedGoogle Scholar
  13. López-Jaramillo P, Silva SY, Rodríguez-Salamanca N, Duran A, Mosquera W, Castillo V. Are nutrition-induced epigenetic changes the link between socioeconomic pathology and cardiovascular diseases? Am J Ther. 2008;15:362–72.PubMedGoogle Scholar
  14. Gallou-Kabani C, Junien C. Nutritional epigenomics of metabolic syndrome: new perspective against the epidemic. Diabetes. 2005;54:1899–906.PubMedGoogle Scholar
  15. López-Jaramillo P, Rey JJ, Gómez-Arbeláez D, Rodríguez YA, López-López J. Combating the type 2 diabetes mellitus epidemic in Latin America: special features demanding innovative actions. Clin Investig Arterioscler. 2011;23:90–9.Google Scholar
  16. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2 · 7 million participants. Lancet. 2011;378:31–40.PubMedGoogle Scholar
  17. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414–31.PubMedGoogle Scholar
  18. Pérez CM, Guzmán M, Ortiz AP, Estrella M, Valle Y, Pérez N, et al. Prevalence of the metabolic syndrome in San Juan, Puerto Rico. Ethn Dis. 2008;18:434–41.PubMedPubMed CentralGoogle Scholar
  19. Medina-Lezama J, Zea-Diaz H, Morey-Vargas OL, Bolaños-Salazar JF, Muñoz-Atahualpa E, Postigo-MacDowall M, et al. Prevalence of the metabolic syndrome in Peruvian Andean hispanics: the PREVENCION study. Diabetes Res Clin Pract. 2007;78:270–81.PubMedGoogle Scholar
  20. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9 · 1 million participants. Lancet. 2011;377:557–67.PubMedPubMed CentralGoogle Scholar
  21. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356–9.PubMedGoogle Scholar
  22. López-Jaramillo P, Rueda-Clausen CF, Silva FA. The utility of different definitions of metabolic syndrome in Andean population. Int J Cardiol. 2007;116:421–2.PubMedGoogle Scholar
  23. Valenzuela AA, Maíz A, Margozzini P, Ferreccio C, Rigotti A, Olea R, et al. Prevalence of metabolic syndrome among Chilean adults. Rev Med Chil. 2010;138:707–14.PubMedGoogle Scholar
  24. Villalpando S, Shamah-Levy T, Rojas R, Aguilar-Salinas CA. Trends for type 2 diabetes and other cardiovascular risk factors in Mexico from 1993–2006. Salud Publica Mex. 2010;52:72–9.Google Scholar
  25. Rojas R, Aguilar-Salinas CA, Jiménez-Corona A, Shamah-Levy T, Rauda J, Avila-Burgos L, et al. Metabolic syndrome in Mexican adults: results from the National Health and Nutrition Survey 2006. Salud Publica Mex. 2010;52:11–8.Google Scholar
  26. Florez H, Silva E, Fernández V, Ryder E, Sulbarán T, Campos G, et al. Prevalence and risk factors associated with the metabolic syndrome and dyslipidemia in White, Black, Amerindian and Mixed Hispanics in Zulia State, Venezuela. Diabetes Res Clin Pract. 2005;69:63–77.PubMedGoogle Scholar
  27. Sempértegui F, Estrella B, Tucker KL, Hamer DH, Narvaez X, Sempértegui M, et al. Metabolic syndrome in the elderly living in marginal peri-urban communities in Quito, Ecuador. Public Health Nutr. 2011;14:758–67.PubMedGoogle Scholar
  28. Rodrigues SL, Baldo MP, Mill JG. Association of waist-stature ratio with hypertension and metabolic syndrome: population-based study. Arq Bras Cardiol. 2010;95:186–91.PubMedGoogle Scholar
  29. Caceres M, Teran CG, Rodriguez S, Medina M. Prevalence of insulin resistance and its association with metabolic syndrome criteria among Bolivian children and adolescents with obesity. BMC Pediatr. 2008;8:31.PubMedPubMed CentralGoogle Scholar
  30. Bustos P, Saez K, Gleisner A, Ulloa N, Calvo C, Asenjo S. Metabolic syndrome in obese adolescents. Pediatr Diabetes. 2010;11:55–60.PubMedGoogle Scholar
  31. Cohen DD, Gómez-Arbeláez D, Camacho PA, Pinzon S, Hormiga C, Trejos-Suarez J, et al. Low muscle strength is associated with metabolic risk factors in Colombian children: the ACFIES study. PLoS One. 2014;9:e93150.PubMedPubMed CentralGoogle Scholar
  32. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310:959–68.PubMedGoogle Scholar
  33. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, et al. Teo KK; Prospective Urban Rural Epidemiology (PURE) Study Investigators: Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011;378:1231–43.PubMedGoogle Scholar
  34. Teo K, Lear S, Islam S, Mony P, Dehghan M, Li W, et al. Pure Investigators: Prevalence of a healthy lifestyle among individuals with cardiovascular disease in high-, middle- and low-income countries: The Prospective Urban Rural Epidemiology (PURE) study. JAMA. 2013;309:1613–21.PubMedGoogle Scholar
  35. Arredondo A, Zuñiga A. Epidemiological changes and financial consequences of hypertension in Latin America: implications for the health system and patients in Mexico. Cad Saude Publica. 2012;28:497–502.PubMedGoogle Scholar
  36. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world–a growing challenge. N Engl J Med. 2007;356:213–5.PubMedGoogle Scholar
  37. López-Jaramillo P, Sánchez RA, Diaz M, Cobos L, Bryce A, Parra Carrillo JZ, et al. Latin American consensus on hypertension in patients with diabetes type 2 and metabolic syndrome. J Hypertens. 2013;31:223–38.PubMedGoogle Scholar
  38. Lopez-Jaramillo P, Molina DI. The 20 × 20 Latin American Society of Hypertension target. J Hypertens. 2015;33:189–90.PubMedGoogle Scholar
  39. Henikoff S, Matzke MA. Exploring and explaining epigenetic effects. Trends Genet. 1997;13:293–5.PubMedGoogle Scholar
  40. Attig L, Gabory A, Junien C. Early nutrition and epigenetic programming: chasing shadows. Curr Opin Clin Nutr Metab Care. 2010;13:284–93.PubMedGoogle Scholar
  41. Probst AV, Dunleavy E, Almouzni G. Epigenetic inheritance during the cell cycle. Nat Rev Mol Cell Biol. 2009;10:192–206.PubMedGoogle Scholar
  42. Bestor TH, Chandler VL, Feinberg AP. Epigenetic effects in eukaryotic gene expression. Dev Genet. 1994;15:458–62.PubMedGoogle Scholar
  43. Ling C, Groop L. Epigenetics: a molecular link between environmental factors and type 2 diabetes. Diabetes. 2009;58:2718–25.PubMedPubMed CentralGoogle Scholar
  44. Gabory A, Attig L, Junien C. Sexual dimorphism in environmental epigenetic programming. Mol Cell Endocrinol. 2009;304:8–18.PubMedGoogle Scholar
  45. VerMilyea MD, O’Neill LP, Turner BM. Transcription-independent heritability of induced histone modifications in the mouse preimplantation embryo. PLoS One. 2009;4:e6086.PubMedPubMed CentralGoogle Scholar
  46. Attig L, Gabory A, Junien C. Nutritional developmental epigenomics: immediate and long-lasting effects. Proc Nutr Soc. 2010;69:221–31.PubMedGoogle Scholar
  47. Weaver IC. Shaping adult phenotypes through early life environments. Birth Defects Res C Embryo Today. 2009;87:314–26.PubMedGoogle Scholar
  48. Karemaker R, Karemaker JM, Kavelaars A, Tersteeg-Kamperman M, Baerts W, Veen S, et al. Effects of neonatal dexamethasone treatment on the cardiovascular stress response of children at school age. Pediatrics. 2008;122:978–87.PubMedGoogle Scholar
  49. Barrès R, Osler ME, Yan J, Rune A, Fritz T, Caidahl K, et al. Non-CpG methylation of the PGC-1alpha promoter through DNMT3B controls mitochondrial density. Cell Metab. 2009;10:189–98.PubMedGoogle Scholar
  50. Plagemann A, Harder T, Brunn M, Harder A, Roepke K, Wittrock-Staar M, et al. Hypothalamic proopiomelanocortin promoter methylation becomes altered by early overfeeding: an epigenetic model of obesity and the metabolic syndrome. J Physiol. 2009;587:4963–76.PubMedPubMed CentralGoogle Scholar
  51. Plagemann A, Roepke K, Harder T, Brunn M, Harder A, Wittrock-Staar M, et al. Epigenetic malprogramming of the insulin receptor promoter due to developmental overfeeding. J Perinat Med. 2010;38:393–400.PubMedGoogle Scholar
  52. Godfrey KM, Gluckman PD, Hanson MA. Developmental origins of metabolic disease: life course and intergenerational perspectives. Trends Endocrinol Metab. 2010;21:199–205.PubMedGoogle Scholar
  53. Burdge GC, Lillycrop KA. Nutrition, epigenetics, and developmental plasticity: implications for understanding human disease. Annu Rev Nutr. 2010;30:315–39.PubMedGoogle Scholar
  54. Cooney CA. Germ cells carry the epigenetic benefits of grandmother’s diet. Proc Natl Acad Sci U S A. 2006;103:17071–2.PubMedPubMed CentralGoogle Scholar
  55. Aguilera O, Fernández AF, Muñoz A, Fraga MF. Epigenetics and environment: a complex relationship. J Appl Physiol (1985). 2010;109:243–51.Google Scholar
  56. Youngson NA, Whitelaw E. Transgenerational epigenetic effects. Annu Rev Genomics Hum Genet. 2008;9:233–57.PubMedGoogle Scholar
  57. Gallou-Kabani C, Vigé A, Gross MS, Junien C. Nutri-epigenomics: lifelong remodelling of our epigenomes by nutritional and metabolic factors and beyond. Clin Chem Lab Med. 2007;45:321–7.PubMedGoogle Scholar
  58. Gluckman PD, Hanson MA, Cooper C, Thornburg KL. Effect of in utero and early-life conditions on adult health and disease. N Engl J Med. 2008;359:61–73.PubMedPubMed CentralGoogle Scholar
  59. Burdge GC, Lillycrop KA, Jackson AA. Nutrition in early life, and risk of cancer and metabolic disease: alternative endings in an epigenetic tale? Br J Nutr. 2009;101:619–30.PubMedGoogle Scholar
  60. Anway MD, Cupp AS, Uzumcu M, Skinner MK. Epigenetic transgenerational actions of endocrine disruptors and male fertility. Science. 2005;308:1466–9.PubMedGoogle Scholar
  61. Anway MD, Skinner MK. Epigenetic transgenerational actions of endocrine disruptors. Endocrinology. 2006;147:43–9.Google Scholar
  62. Jirtle RL, Skinner MK. Environmental epigenomics and disease susceptibility. Nat Rev Genet. 2007;8:253–62.PubMedGoogle Scholar
  63. Barker DJ, Martyn CN. The maternal and fetal origins of cardiovascular disease. J Epidemiol Community Health. 1992;46:8–11.PubMedPubMed CentralGoogle Scholar
  64. Jackson AA, Burdge GC, Lillycrop KA. Diet, nutrition and modulation of genomic expression in fetal origins of adult disease. World Rev Nutr Diet. 2010;101:56–72.PubMedGoogle Scholar
  65. Chmurzynska A. Fetal programming: link between early nutrition, DNA methylation, and complex diseases. Nutr Rev. 2010;68:87–98.PubMedGoogle Scholar
  66. SzarcvelSzic K, Ndlovu MN, Haegeman G, VandenBerghe W. Nature or nurture: let food be your epigenetic medicine in chronic inflammatory disorders. Biochem Pharmacol. 2010;80:1816–32.Google Scholar
  67. American Association for Cancer Research Human Epigenome Task Force; European Union, Network of Excellence, Scientific Advisory Board. Moving AHEAD with an international human epigenome project. Nature. 2008;454:711–5.Google Scholar
  68. De Assis S, Hilakivi-Clarke L. Timing of dietary estrogenic exposures and breast cancer risk. Ann N Y Acad Sci. 2006;1089:14–35.PubMedGoogle Scholar
  69. Guerrero-Bosagna CM, Sabat P, Valdovinos FS, Valladares LE, Clark SJ. Epigenetic and phenotypic changes result from a continuous pre and post natal dietary exposure to phytoestrogens in an experimental population of mice. BMC Physiol. 2008;8:17.PubMedPubMed CentralGoogle Scholar
  70. Hunter P. We are what we eat. The link between diet, evolution and non-genetic inheritance. EMBO Rep. 2008;9:413–5.PubMedPubMed CentralGoogle Scholar
  71. Painter RC, Osmond C, Gluckman P, Hanson M, Phillips DI, Roseboom TJ. Transgenerational effects of prenatal exposure to the Dutch famine on neonatal adiposity and health in later life. BJOG. 2008;115:1243–9.PubMedGoogle Scholar
  72. Lumey LH, Stein AD. Transgenerational effects of prenatal exposure to the Dutch famine. BJOG. 2009;116:868.PubMedGoogle Scholar
  73. Roseboom T, de Rooij S, Painter R. The Dutch famine and its long-term consequences for adult health. Early Hum Dev. 2006;82:485–91.PubMedGoogle Scholar
  74. Sinclair KD, Allegrucci C, Singh R, Gardner DS, Sebastian S, Bispham J, et al. DNA methylation, insulin resistance, and blood pressure in offspring determined by maternal periconceptional B vitamin and methionine status. Proc Natl Acad Sci USA. 2007;104:19351–6.PubMedPubMed CentralGoogle Scholar
  75. Kwong WY, Miller DJ, Ursell E, Wild AE, Wilkins AP, Osmond C, et al. Imprinted gene expression in the rat embryo-fetal axis is altered in response to periconceptional maternal low protein diet. Reproduction. 2006;132:265–77.PubMedGoogle Scholar
  76. Kwong WY, Miller DJ, Wilkins AP, Dear MS, Wright JN, Osmond C, et al. Maternal low protein diet restricted to the preimplantation period induces a gender-specific change on hepatic gene expression in rat fetuses. Mol Reprod Dev. 2007;74:48–56.PubMedGoogle Scholar
  77. Katari S, Turan N, Bibikova M, Erinle O, Chalian R, Foster M, et al. DNA methylation and gene expression differences in children conceived in vitro or in vivo. Hum Mol Genet. 2009;18:3769–78.PubMedPubMed CentralGoogle Scholar
  78. Pinney SE, Simmons RA. Epigenetic mechanisms in the development of type 2 diabetes. Trends Endocrinol Metab. 2010;21:223–9.PubMedGoogle Scholar
  79. Raychaudhuri N, Raychaudhuri S, Thamotharan M, Devaskar SU. Histone code modifications repress glucose transporter 4 expression in the intrauterine growth-restricted offspring. J Biol Chem. 2008;283:13611–26.PubMedPubMed CentralGoogle Scholar
  80. Levent E, Atik T, Darcan S, Ulger Z, Gökşen D, Ozyürek AR. The relation of arterial stiffness with intrauterine growth retardation. Pediatr Int. 2009;51:807–11.PubMedGoogle Scholar
  81. Martyn CN, Barker DJ, Jespersen S, Greenwald S, Osmond C, Berry C. Growth in utero, adult blood pressure, and arterial compliance. Br Heart J. 1995;73:116–21.PubMedPubMed CentralGoogle Scholar
  82. Liew G, Wang JJ, Duncan BB, Klein R, Sharrett AR, Brancati F, et al. Low birthweight is associated with narrower arterioles in adults. Hypertension. 2008;51:933–8.PubMedGoogle Scholar
  83. Martin H, Gazelius B, Norman M. Impaired acetylcholine-induced vascular relaxation in low birth weight infants: implications for adult hypertension? Pediatr Res. 2000;47:457–62.PubMedGoogle Scholar
  84. Szostak-Wegierek D. Intrauterine nutrition: long-term consequences for vascular health. Int J Womens Health. 2014;6:647–56.PubMedPubMed CentralGoogle Scholar
  85. Wang T, Liu C, Feng C, Wang X, Lin G, Zhu Y, et al. IUGR alters muscle fiber development and proteome in fetal pigs. Front Biosci (Landmark Ed). 2013;18:598–607.Google Scholar
  86. Lopez-Jaramillo P, Cohen DD, Gómez-Arbeláez D, Bosch J, Dyal L, Yusuf S, et al. Association of handgrip strength to cardiovascular mortality in pre-diabetic and diabetic patients: a subanalysis of the ORIGIN trial. Int J Cardiol. 2014;174:458–61.PubMedGoogle Scholar
  87. McConnell JM, Petrie L. Mitochondrial DNA turnover occurs during preimplantation development and can be modulated by environmental factors. Reprod Biomed Online. 2004;9:418–24.PubMedGoogle Scholar
  88. Petrie L, Duthie SJ, Rees WD, McConnell JM. Serum concentrations of homocysteine are elevated during early pregnancy in rodent models of fetal programming. Br J Nutr. 2002;88:471–7.PubMedGoogle Scholar
  89. Thompson JG, Gardner DK, Pugh PA, McMillan WH, Tervit HR. Lamb birth weight is affected by culture system utilized during in vitro pre-elongation development of ovine embryos. Biol Reprod. 1995;53:1385–91.PubMedGoogle Scholar
  90. Ecker DJ, Stein P, Xu Z, Williams CJ, Kopf GS, Bilker WB, et al. Long-term effects of culture of preimplantation mouse embryos on behavior. Proc Natl Acad Sci U S A. 2004;101:1595–600.PubMedPubMed CentralGoogle Scholar
  91. Kwong WY, Wild AE, Roberts P, Willis AC, Fleming TP. Maternal undernutrition during the preimplantation period of rat development causes blastocyst abnormalities and programming of postnatal hypertension. Development. 2000;127:4195–202.PubMedGoogle Scholar
  92. Ashworth CJ, Toma LM, Hunter MG. Nutritional effects on oocyte and embryo development in mammals: implications for reproductive efficiency and environmental sustainability. Philos Trans R Soc Lond B Biol Sci. 2009;364:3351–61.PubMedPubMed CentralGoogle Scholar
  93. Snoeck A, Remacle C, Reusens B, Hoet JJ. Effect of a low protein diet during pregnancy on the fetal rat endocrine pancreas. Biol Neonate. 1990;57:107–18.PubMedGoogle Scholar
  94. Dahri S, Snoeck A, Reusens-Billen B, Remacle C, Hoet JJ. Islet function in offspring of mothers on low-protein diet during gestation. Diabetes. 1991;40:115–20.PubMedGoogle Scholar
  95. Hales CN, Barker DJ, Clark PM, Cox LJ, Fall C, Osmond C, et al. Fetal and infant growth and impaired glucose tolerance at age 64. BMJ. 1991;303:1019–22.PubMedPubMed CentralGoogle Scholar
  96. Barker DJ, Hales CN, Fall CH, Osmond C, Phipps K, Clark PM. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia. 1993;36:62–7.PubMedGoogle Scholar
  97. Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, Ballestar ML, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA. 2005;102:10604–9.PubMedPubMed CentralGoogle Scholar
  98. Christensen BC, Houseman EA, Marsit CJ, Zheng S, Wrensch MR, Wiemels JL, et al. Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CpG island context. PLoS Genet. 2009;5:e1000602.PubMedPubMed CentralGoogle Scholar
  99. Wierda RJ, Geutskens SB, Jukema JW, Quax PH, van den Elsen PJ. Epigenetics in atherosclerosis and inflammation. J Cell Mol Med. 2010;14:1225–40.PubMedPubMed CentralGoogle Scholar
  100. Lund G, Zaina S. Epigenetics, transgenerational effects and risk factors for atherosclerosis. Curr Opin Lipidol. 2009;20:150–1.PubMedGoogle Scholar
  101. Lund G, Zaina S. Atherosclerosis risk factors can impose aberrant DNA methylation patterns: a tale of traffic and homocysteine. Curr Opin Lipidol. 2009;20:448–9.PubMedGoogle Scholar
  102. Waldo SW, Li Y, Buono C, Zhao B, Billings EM, Chang J, et al. Heterogeneity of human macrophages in culture and in atherosclerotic plaques. Am J Pathol. 2008;172:1112–26.PubMedPubMed CentralGoogle Scholar
  103. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006;113:898–918.PubMedGoogle Scholar
  104. Rueda-Clausen CF, Lahera V, Calderón J, Bolivar IC, Castillo VR, Gutiérrez M, et al. The presence of abdominal obesity is associated with changes in vascular function independently of other cardiovascular risk factors. Int J Cardiol. 2010;139:32–41.PubMedGoogle Scholar
  105. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case–control study. Lancet. 2005;366:1640–9.PubMedGoogle Scholar
  106. O’Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case–control study. Lancet. 2010;376:112–23.PubMedGoogle Scholar
  107. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56:1113–32.PubMedGoogle Scholar
  108. Aschner P, Ruiz A, Balkau B, Massien C, Haffner SM, Latin America and the Caribbean International Day for Evaluation of Abdominal Adiposity (IDEA) National Coordinators and Investigators. Association of abdominal adiposity with diabetes and cardiovascular disease in Latin America. J Clin Hypertens (Greenwich). 2009;11:769–74.Google Scholar
  109. Gregory CO, Corvalán C, Ramirez-Zea M, Martorell R, Stein AD. Detection of cardio-metabolic risk by BMI and waist circumference among a population of Guatemalan adults. Public Health Nutr. 2008;11:1037–45.PubMedGoogle Scholar
  110. Katulanda P, Jayawardena MA, Sheriff MH, Matthews DR. Derivation of anthropometric cut-off levels to define CVD risk in Sri Lankan adults. Br J Nutr. 2011;105:1084–90.PubMedGoogle Scholar
  111. Perez M, Casas JP, Cubillos-Garzón LA, Serrano NC, Silva F, Morillo CA, et al. Using waist circumference as a screening tool to identify Colombian subjects at cardiovascular risk. Eur J Cardiovasc Prev Rehabil. 2003;10:328–35.PubMedGoogle Scholar
  112. Garcia RG, Cifuentes AE, Caballero RS, Sanchez L, López-Jaramillo P. A proposal for an appropriate central obesity diagnosis in Latin American population. Int J Cardiol. 2006;110:263–4.PubMedGoogle Scholar
  113. Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93:359–404.PubMedGoogle Scholar
  114. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology. 2004;145:2273–82.PubMedGoogle Scholar
  115. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab. 2000;11:327–32.PubMedGoogle Scholar
  116. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab. 1998;83:847–50.PubMedGoogle Scholar
  117. López-Jaramillo P, Pradilla LP, Castillo VR, Lahera V. Socioeconomic pathology as a cause of regional differences in the prevalence of metabolic syndrome and pregnancy-induced hypertension. Rev Esp Cardiol. 2007;60:168–78.PubMedGoogle Scholar
  118. López-Jaramillo P, Casas JP, Morillo CA. C-reactive protein and cardiovascular diseases in Andean population. Circulation. 2002;105:E10.PubMedGoogle Scholar
  119. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes. 2007;56:1010–3.PubMedGoogle Scholar
  120. Accini JL, Sotomayor A, Trujillo F, Barrera JG, Bautista L, López-Jaramillo P. Colombian study to assess the use of noninvasive determination of endothelium-mediated vasodilatation (CANDEV). Normal values and factors associated. Endothelium. 2001;8:157–66.PubMedGoogle Scholar
  121. Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999;340:115–26.PubMedGoogle Scholar
  122. Gómez-Arbeláez D, López-Jaramillo P. Mechanisms of acute coronary syndromes. N Engl J Med. 2013;369:882.PubMedGoogle Scholar
  123. Bogaty P, Poirier P, Simard S, Boyer L, Solymoss S, Dagenais GR. Biological profiles in subjects with recurrent acute coronary events compared with subjects with long-standing stable angina. Circulation. 2001;103:3062–8.PubMedGoogle Scholar
  124. Bautista LE, López-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens. 2001;19:857–61.PubMedGoogle Scholar
  125. Teran E, Escudero C, Moya W, Flores M, Vallance P, Lopez-Jaramillo P. Elevated C-reactive protein and pro-inflammatory cytokines in Andean women with pre-eclampsia. Int J Gynaecol Obstet. 2001;75:243–9.PubMedGoogle Scholar
  126. García RG, Celedón J, Sierra-Laguado J, Alarcón MA, Luengas C, Silva F, et al. Raised C-reactive protein and impaired flow-mediated vasodilation precede the development of preeclampsia. Am J Hypertens. 2007;20:98–103.PubMedGoogle Scholar
  127. Garcia RG, Perez M, Maas R, Schwedhelm E, Böger RH, López-Jaramillo P. Plasma concentrations of asymmetric dimethylarginine (ADMA) in metabolic syndrome. Int J Cardiol. 2007;122:176–8.PubMedGoogle Scholar
  128. López-Jaramillo P, Herrera E, Garcia RG, Camacho PA, Castillo VR. Inter-relationships between body mass index, C-reactive protein and blood pressure in a Hispanic pediatric population. Am J Hypertens. 2008;21:527–32.PubMedGoogle Scholar
  129. López-Jaramillo P, Gómez-Arbeláez D, López-López J, López-López C, Martínez-Ortega J, Gómez-Rodríguez A, et al. The role of leptin/adiponectin ratio in metabolic syndrome and diabetes. Horm Mol Biol Clin Investig. 2014;18:37–45.PubMedGoogle Scholar
  130. Medzhitov R, Horng T. Transcriptional control of the inflammatory response. Nat Rev Immunol. 2009;9:692–703.PubMedGoogle Scholar
  131. Pasparakis M. Regulation of tissue homeostasis by NF-kappa B signalling: implications for inflammatory diseases. Nat Rev Immunol. 2009;9:778–88.PubMedGoogle Scholar
  132. Ghosh S, Hayden MS. New regulators of NF-kappa B in inflammation. Nat Rev Immunol. 2008;8:837–48.PubMedGoogle Scholar
  133. Karin M, Greten FR. NF-kappa B: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5:749–59.PubMedGoogle Scholar
  134. Chen LF, Greene WC. Shaping the nuclear action of NF-kappa B. Nat Rev Mol Cell Biol. 2004;5:392–401.PubMedGoogle Scholar
  135. Grivennikov SI, Karin M. Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev. 2010;20:65–71.PubMedGoogle Scholar
  136. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010;140:197–208.PubMedPubMed CentralGoogle Scholar
  137. Olefsky JM. IKK epsilon: a bridge between obesity and inflammation. Cell. 2009;138:834–6.PubMedGoogle Scholar
  138. Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell. 2010;140:900–17.PubMedPubMed CentralGoogle Scholar
  139. Mandl J, Mészáros T, Bánhegyi G, Hunyady L, Csala M. Endoplasmic reticulum: nutrient sensor in physiology and pathology. Trends Endocrinol Metab. 2009;20:194–201.PubMedGoogle Scholar
  140. Karin M. Nuclear factor-kappa B in cancer development and progression. Nature. 2006;441:431–6.PubMedGoogle Scholar
  141. Perkins ND. Integrating cell-signalling pathways with NF-kappa B and IKK function. Nat Rev Mol Cell Biol. 2007;8:49–62.PubMedGoogle Scholar
  142. Nakanishi C, Toi M. Nuclear factor-kappa B inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer. 2005;5:297–309.PubMedGoogle Scholar
  143. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med. 2005;11:191–8.PubMedGoogle Scholar
  144. Tennant DA, Durán RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer. 2010;10:267–77.PubMedGoogle Scholar
  145. De Santa F, Totaro MG, Prosperini E, Notarbartolo S, Testa G, Natoli G. The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing. Cell. 2007;130:1083–94.PubMedGoogle Scholar
  146. Ghisletti S, Barozzi I, Mietton F, Polletti S, De Santa F, Venturini E, et al. Identification and characterization of enhancers controlling the inflammatory gene expression program in macrophages. Immunity. 2010;32:317–28.PubMedGoogle Scholar
  147. Ghisletti S, Huang W, Ogawa S, Pascual G, Lin ME, Willson TM, et al. Parallel sumoylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma. Mol Cell. 2007;25:57–70.PubMedPubMed CentralGoogle Scholar
  148. Xu J, Watts JA, Pope SD, Gadue P, Kamps M, Plath K, et al. Transcriptional competence and the active marking of tissue-specific enhancers by defined transcription factors in embryonic and induced pluripotent stem cells. Genes Dev. 2009;23:2824–38.PubMedPubMed CentralGoogle Scholar
  149. Natoli G, Saccani S, Bosisio D, Marazzi I. Interactions of NF-kappa B with chromatin: the art of being at the right place at the right time. Nat Immunol. 2005;6:439–45.PubMedGoogle Scholar
  150. Hager GL, McNally JG, Misteli T. Transcription dynamics. Mol Cell. 2009;35:741–53.PubMedGoogle Scholar
  151. Sung MH, Salvatore L, De Lorenzi R, Indrawan A, Pasparakis M, Hager GL, et al. Sustained oscillations of NF-kappa B produce distinct genome scanning and gene expression profiles. PLoS One. 2009;4:e7163.PubMedPubMed CentralGoogle Scholar
  152. Delage B, Dashwood RH. Dietary manipulation of histone structure and function. Annu Rev Nutr. 2008;28:347–66.PubMedPubMed CentralGoogle Scholar
  153. Link A, Balaguer F, Goel A. Cancer chemoprevention by dietary polyphenols: promising role for epigenetics. Biochem Pharmacol. 2010;80:1771–92.PubMedPubMed CentralGoogle Scholar
  154. Hauser AT, Jung M. Targeting epigenetic mechanisms: potential of natural products in cancer chemoprevention. Planta Med. 2008;74:1593–601.PubMedGoogle Scholar
  155. Kirk H, Cefalu WT, Ribnicky D, Liu Z, Eilertsen KJ. Botanicals as epigenetic modulators for mechanisms contributing to development of metabolic syndrome. Metabolism. 2008;57:16–23.Google Scholar
  156. Fang M, Chen D, Yang CS. Dietary polyphenols may affect DNA methylation. J Nutr. 2007;137:223–8.Google Scholar
  157. Ramirez-Carrozzi VR, Braas D, Bhatt DM, Cheng CS, Hong C, Doty KR, et al. A unifying model for the selective regulation of inducible transcription by CpG islands and nucleosome remodeling. Cell. 2009;138:114–28.PubMedPubMed CentralGoogle Scholar
  158. VandenBerghe W, Ndlovu MN, Hoya-Arias R, Dijsselbloem N, Gerlo S, Haegeman G. Keeping up NF-kappa B appearances: epigenetic control of immunity or inflammation-triggered epigenetics. Biochem Pharmacol. 2006;72:1114–31.Google Scholar
  159. O’Dea E, Hoffmann A. The regulatory logic of the NF-kappa B signaling system. Cold Spring Harb Perspect Biol. 2010;2:a000216.PubMedPubMed CentralGoogle Scholar
  160. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell. 2008;132:344–62.PubMedGoogle Scholar
  161. Natoli G, De Santa F. Shaping alternative NF-kappaB-dependent gene expression programs: new clues to specificity. Cell Death Differ. 2006;13:693–6.PubMedGoogle Scholar
  162. Ford E, Thanos D. The transcriptional code of human IFN-beta gene expression. Biochim Biophys Acta. 2010;1799:328–36.PubMedGoogle Scholar

Copyright

© Lopez-Jaramillo et al.; licensee BioMed Central. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement